True Wealth Design’s Zentalis Pharmaceuticals ZNTL Stock Holding History

True Wealth Design’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9	Closed	-$11	–	2906
2025 Q2	$11	Sell	9 -71	-89%	-$94	﹤0.01%	2541
2025 Q1	$128	Buy	80 +67	+515%	+$144	﹤0.01%	2119
2024 Q4	$40	Sell	13 -198	-94%	-$649	﹤0.01%	1324
2024 Q3	$777	Buy	+211	New	+$767	﹤0.01%	1022

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

True Wealth Design's ZNTL Position: Q3 2025 in Review

True Wealth Design sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 9 shares — an estimated $11 sold.

True Wealth Design first reported a position in ZNTL in Q3 2024 and held it in 4 quarters. The position peaked at $777 in Q3 2024. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

True Wealth Design reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 9 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $11.
True Wealth Design first reported a position in Zentalis Pharmaceuticals in Q3 2024 and held it in 4 quarters.
True Wealth Design's Zentalis Pharmaceuticals position peaked at $777 in Q3 2024.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.